Safety and Efficacy of Buprenorphine/Naloxone in Opioid-Dependent Patients
- First Online:
- 153 Downloads
Background: Opioid dependence is a growing problem. Methadone is an established agent for the treatment of opioid dependence, but there is a risk of this agent being abused, a potential for interaction with antiretroviral agents and a risk of cardiac toxicity. Another option is the partial μ-opioid receptor opioid agonist buprenorphine, which has been used successfully to manage opioid dependence. While the risk of abuse is lower than that for methadone, there is still a risk. The sublingual combination formulation of buprenorphine and the opioid receptor antagonist naloxone (buprenorphine/naxolone) is a newer agent with reduced abuse potential, and has been shown to have promising efficacy for opioid dependence.
Objectives: We describe the results of an observational study investigating the safety and efficacy of buprenorphine/naloxone in opioid-dependent patients.
Methods: A total of 77 patients were included and were switched from buprenorphine to sublingual tables of buprenorphine/naloxone; the buprenorphine dosage was titrated to achieve good control of withdrawal symptoms. The prevalence of withdrawal symptoms, craving, constipation, cramps, insomnia, sexual activity, depression, sweating, distress, bone/joint pain and drowsiness were compared over the first 30 days of treatment (period 1) and the total 120-day study duration (period 2).
Results: The average buprenorphine/naloxone dose in period 1 was 7.3 mg/day and 12.7 mg/day in period 2. Most patients did not experience any withdrawal symptoms in either period 1 or period 2. Fewer than 20% of patients experienced any cravings over the 120-day study period. Importantly, the adverse effects observed were usually mild, with very few patients experiencing significant adverse effects.
Conclusions: This study shows that buprenorphine/naloxone is an effective and well tolerated treatment for opioid withdrawal when the dosage is titrated to achieve good control of withdrawal symptoms. Switching from buprenorphine alone to buprenorphine/naloxone was possible with very little discomfort for the patient and effective retained patients in treatment.
- 1.US Department of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol TIP 40. 2004Google Scholar
- 2.National Institute on Drug Abuse. Principles of drug addiction treatment: a research based guide. Evidence-based approaches to drug addiction treatment. [cited 2009 21 Oct]; Available from: http://www.drugabuse.gov/PODAT/ Evidence.html#PharmGoogle Scholar
- 4.Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003 (2): CD002207Google Scholar
- 5.Prescribing Information — Methadone (Italy). [cited 2009 14 Nov]; Available from: http://www.pharmamarketing.it/ cont/020ser/050pro/default.asp?method=Mostra_Contenuto &id_cont=61641Google Scholar
- 8.Chapleo CB, Walter DS. The buprenorphine-naloxone combination product. Res Clin Forums 1997; 19(2): 55–8Google Scholar
- 15.European Medicines Agency. Scientific discussion (Suboxone) [online]. [cited 2007 21 Oct]; Available from: http://www. emea.europa.eu/humandocs/PDFs/EPAR/suboxone/069706 en6.pdfGoogle Scholar
- 19.Kamien JB, Branstetter SA, Amass LA. Buprenorphinenaloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10(4): 5–18Google Scholar
- 21.Reckitt Benckiser Pharmaceuticals Inc. Suboxone (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets)/Subutex (buprenorphine HCl sublingual tablets): US prescribing information [online]. [cited 2009 16 November]; Available from: http://http://www.suboxone.com/patients/pi